Andrew S. Levey

Andrew S. Levey

Top Cited Scholar 2024
Auto-generated profile, based on publicly available information

Andrew S. Levey

Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2009 in Annals of Internal Medicine
Verified
Journal Article
Closed access
ALAndrew S. Levey
Andrew S. Levey
LSLesley A. Stevens
Lesley A. Stevens
CSChristopher H. Schmid
Christopher H. Schmid
YZYaping (Lucy) Zhang
Yaping (Lucy) Zhang
ACAlejandro F. Castro
Alejandro F. Castro
FCfor the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)*
for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)*
The Modification of Diet in Renal Disease (MDRD) Study equation underestimates glomerular filtration rate (GFR) in patients with mild kidney disease. Levey and associates therefore developed and va... Background: Equations to estimate glomerular filtration rate (GFR) are routinely used to assess kidney function. Current equations have limited precision and systematically underestimate measured G...

1 July 2011 in Kidney International
Verified
Journal Article
Closed access
ALAndrew S. Levey
Andrew S. Levey
PJPaul E. de Jong
Paul E. de Jong
JCJosef Coresh
Josef Coresh
MNMeguid El Nahas
Meguid El Nahas
BABrad C. Astor
Brad C. Astor
KEKai-Uwe Eckardt
Kai-Uwe Eckardt

1 January 2012 in The Lancet
Verified
Journal Article
Closed access
ALAndrew S Levey
Andrew S Levey
JCJosef Coresh
Josef Coresh


1 June 2020 in Kidney International
Verified
Journal Article
Open access
ALAndrew S. Levey
Andrew S. Levey
KEKai-Uwe Eckardt
Kai-Uwe Eckardt
NDNijsje M. Dorman
Nijsje M. Dorman
SCStacy L. Christiansen
Stacy L. Christiansen
EHEwout J. Hoorn
Ewout J. Hoorn
WWWolfgang C. Winkelmayer
Wolfgang C. Winkelmayer
The worldwide burden of kidney disease is rising, but public awareness remains limited, underscoring the need for more effective communication by stakeholders in the kidney health community. Despite this need for clarity, the nomenclature for describing kidney function and disease lacks uniformity. In June 2019, Kidney Disease: Improving Global Outcomes (KDIGO) convened a Consensus Conference with the goal of standardizing and refining the nomenclature used in the English language to describe kidney function and disease, and of developing a glossary that could be used in scientific publications. Guiding principles of the conference were that the revised nomenclature should be patient-centered, precise, and consistent with nomenclature used in the KDIGO guidelines. Conference attendees reached general consensus on the following recommendations: (i) to use "kidney" rather than "renal" or "nephro-" when referring to kidney disease and kidney function; (ii) to use "kidney failure" with appropriate descriptions of presence or absence of symptoms, signs, and treatment, rather than "end-stage kidney disease"; (iii) to use the KDIGO definition and classification of acute kidney diseases and disorders (AKD) and acute kidney injury (AKI), rather than alternative descriptions, to define and classify severity of AKD and AKI; (iv) to use the KDIGO definition and classification of chronic kidney disease (CKD) rather than alternative descriptions to define and classify severity of CKD; and (v) to use specific kidney measures, such as albuminuria or decreased glomerular filtration rate (GFR), rather than "abnormal" or "reduced" kidney function to describe alterations in kidney structure and function. A proposed 5-part glossary contains specific items for which there was general agreement. Conference attendees acknowledged limitations of the recommendations and glossary, but they considered standardization of scientific nomenclature to be essential for improving communication.

1 December 2014 in American Journal of Kidney Diseases
Verified
Journal Article
Open access
PDF file
ALAndrew S. Levey
Andrew S. Levey
LILesley A. Inker
Lesley A. Inker
KMKunihiro Matsushita
Kunihiro Matsushita
TGTom Greene
Tom Greene
KWKerry Willis
Kerry Willis
JCJosef Coresh
Josef Coresh
The US Food and Drug Administration currently accepts halving of glomerular filtration rate (GFR), assessed as doubling of serum creatinine level, as a surrogate end point for the development of kidney failure in clinical trials of kidney disease progression. A doubling of serum creatinine level generally is a late event in chronic kidney disease (CKD); thus, there is great interest in considering alternative end points for clinical trials to shorten their duration, reduce sample size, and extend their conduct to patients with earlier stages of CKD. However, the relationship between lesser declines in GFR and the subsequent development of kidney failure has not been well characterized. The National Kidney Foundation and Food and Drug Administration sponsored a scientific workshop to critically examine available data to determine whether alternative GFR-based end points have sufficiently strong relationships with important clinical outcomes of CKD to be used in clinical trials. Based on a series of meta-analyses of cohorts and clinical trials and simulations of trial designs and analytic methods, the workshop concluded that a confirmed decline in estimated GFR of 30% over 2 to 3 years may be an acceptable surrogate end point in some circumstances, but the pattern of treatment effects on GFR must be examined, specifically acute effects on estimated GFR. An estimated GFR decline of 40% may be more broadly acceptable than a 30% decline across a wider range of baseline GFRs and patterns of treatment effects on GFR. However, there are other circumstances in which these end points could lead to a reduction in statistical power or erroneous conclusions regarding benefits or harms of interventions. We encourage careful consideration of these alternative end points in the design of future clinical trials.